

Tessin - Sales rebound pushed to Q1

Redeye updates its estimates after reviewing Tessin's Q4 report, which came in below our expectations. The weaker result is due to the positive impact from the Pollen Street agreement being postponed to Q1 2025. Excluding extraordinary costs, the result is not as weak as it might initially appear. We have made downward estimate revisions following the report.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Tessin - Sales rebound pushed to Q1